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Abstract
Schizophrenia is a highly heritable, common mental illness, affecting 1% of the population worldwide.
It is currently diagnosed using exclusive clinical criteria, and at present there are no genetic tests to
facilitate this process. There are also no reliable means to predict who will develop the disease in later
life. Genetic counselling uses crude estimates of risk based on family history, as the strongest
predictive factor is having an affected first-degree relative. It has recently become apparent that large
de novo deletions in the genome (copy number variants, or CNVs) can increase risk of the disease by
tenfold or more. The purpose of this report is to assess whether these ‘high risk’ pathogenic CNVs
might be useful in a clinical genetic or diagnostic setting. Routine use of laboratory techniques such as
de novo
procedures for referrals to clinical genetics. The lack of disease specificity of CNVs presents
problems for their use in diagnosis at present. Currently, there is also insufficient evidence in relation
to schizophrenia to suggest that clear clinical benefit would be gained from learning one’s genetic
status pre-symptomatically. However, this is likely to change rapidly in the near future as knowledge
of the genetic and environmental basis of schizophrenia accrues and increasingly effective measures
for early intervention and risk reduction are developed.
Introduction and context
Schizophrenia is a severe mental illness, with heritability
estimated at over 80% and onset in adolescence or early
adulthood [1]. Its aetiology is complex and multifac-
torial, involving interaction between multiple genetic
and environmental factors, and therefore the identifica-
tion of the underlying genetic basis has proven difficult.
The working hypothesis for genetic influences on
schizophrenia has been the ‘common disease, common
allele’ model, in which the illness is caused by combina-
tions of genetic variants which are frequent in the
populations (for example, a risk allele frequency of more
than 5%), each contributing a modest effect. Over 1,000
genetic association studies have been published, with
largely inconsistent results, but a recent meta-analysis
has identified 16 genes with nominally significant effects
and an average pooled odds ratio of 1.23 [2]. Genome-
wide approaches examining common single-nucleotide
ZNF804A gene, which has a relative risk of
about 1.1] [3]. These variants have extremely low
penetrance; that is, the vast majority of those who carry
them do not develop schizophrenia. Because of this,
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comparative genome hybridisation will reveal these CNVs in standard investigative
polymorphisms (SNPs) for association with schizophrenia
are also beginning to yield results [for example, an
SNP in the
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limited utility in clinical genetics, at least in isolation.
The alternative ‘rare variant’ model proposes that genetic
variants predisposing to schizophrenia are penetrant
mutations, which are of recent origin and individually
rare, even specific to single cases or families [4]. A severe
mutation such as a deleterious amino acid change
on a protein or a deletion in any of the genes involved
in neurodevelopmental pathways may lead to a psycho-
pathological phenotype; variable expression or pene-
trance may arise by genetic or epigenetic ‘second hits’ or
simply by chance [5]. One such mutation is a copy
number variant (CNV) on chromosome 22which deletes
1.5 to 3 million base pairs of DNA and causes 22q11.2
deletion syndrome (velocardiofacial syndrome, or
VCFS). This is a well-established risk factor for schizo-
phrenia and other neuropsychiatric phenotypes such as
autism spectrum disorders; at least 25% of subjects with
a deletion develop psychosis [6]. As discussed below,
there is evidence that CNVs such as 22q11.2 deletion
may play an important role in the aetiology of
schizophrenia [7].
Thus, it is possible to conceptualise the genetics of
schizophrenia as a disorder made up of genetic risk
conferred by three types of variants: common low-risk
sequence variants such as SNPs which increase risk by
1.1- to 2-fold, rare CNVs such as the VCFS deletion which
increase the risk of schizophrenia by 3- to 50-fold, and
rare deleterious sequence variants such as non-synon-
ymous SNPs. Current commercially available micro-
arrays cannot easily detect association with rare SNP
variants [8] and therefore large-scale DNA sequencing is
required for their discovery, so less is known about the
role of these variants in complex disorders such as
schizophrenia. It is possible to speculate that 10-20% of
genetic risk is from CNVs, a similar percentage from rare
sequence variants, and the remainder from many
common low-risk polymorphisms [9]. A better under-
standing of the genetic (and indeed environmental)
basis of schizophrenia may facilitate both risk prediction
and diagnosis.
It is theoretically possible to use these various types of
genetic susceptibility variants to predict risk. Using
Crohn’s disease (CD) as a model of a common complex
disorder, Lewis et al. [10] developed methods to estimate
disease risks using both genetic and environmental risk
factors. They found that high absolute risks of CD can be
obtained by incorporating information on smoking,
family history and NOD2 gene mutations. Additional
information on genetic risk can be incorporated into this
model as it arises to improve risk prediction. This
approach should have utility in the clinical setting for
both genetic counselling and behavioural modification
to reduce risk (for example, smoking cessation).
Recent advances
In addition to 22q11.2 deletions, high-risk newly
occurring deletions and duplications of DNA (CNVs)
have recently emerged as genomic risk factors
for common brain disorders, including schizophrenia,
autism and mental retardation [7,11,12]. This involves
an excess of rare de novo CNVs across the genome as a
whole [5,13], which at an individual level probably
represents the damaging effect of very large mutations
on brain function [14]. Some of these may be ‘private’
pathogenic mutations possibly unique to a single
individual. Others appear to be recurrent mutations at
specific sites, such as on chromosomes 1q21.1, 15q11.2,
15q13.3 and the neurexin 1 (NRXN1) gene at 2p16.3
[14-18]. These CNVs are not specific to any particular
psychiatric diagnosis and can give rise to a range of
phenotypes, from autism to epilepsy [12,19-22].
These pathogenic CNVs tend to be rare in the popu-
lation: deletions at 1q21.1 and 15q13.3 occur in about
1/500 patients with schizophrenia compared with
1/5,000 controls without neuropsychiatric illness
[15,16]. In idiopathic generalized epilepsy, however,
deletions at 15q13.3 occur in as many as 1/100 of cases
[21], whereas the 15q11.2 deletion occurs in about
1/200 patients with schizophrenia [15]. These patho-
genic CNVs have a high odds ratio for risk, at around
3- to 10-fold increased risk, in contrast to common
variants, which show odds ratios between 1 and 2. Thus,
the penetrance of the pathogenic CNVs discovered so far
is intermediate between common variants and the high-
risk variants associated with syndromes commonly used
in a clinical genetic setting, at between 2 and 9% for
schizophrenia, compared with 11-55% for VCFS dele-
tions [Vassos et al.., personal communication]. Given that
these variants can give rise to multiple neuropsychiatric
phenotypes, the overall penetrance for any disorder is
likely to be considerably higher; for example, although
the penetrance for 15q13.3 deletions in schizophrenia is
6-9%, penetrance for idiopathic generalized epilepsy is
much higher [20, Vassos et al., personal communication].
Implications for clinical practice
These findings will impact on clinical practice in two
areas, diagnosis and risk assessment (genetic counsel-
ling). At present, schizophrenia is diagnosed using
clinical criteria, which means that because of the low
yield of clinically relevant variants (such as the 22q11.2
VCFS deletion) patients with schizophrenia are not
commonly assessed by genetic testing. However, this
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and their clinical relevance becomes more widely
understood. In addition, children who show idiopathic
developmental delay (for example, intellectual disabi-
lity, language delay or both) or ‘chromosomal’ pheno-
type (that is, developmental delay in association with
growth retardation, facial dysmorphism and minor or
major congenital abnormalities) are usually assessed in
a clinical genetic setting. Here, conventional cytogenetic
analysis is being replaced by CGH and other DNA-based
methods because they have the potential to detect the
majority of microscopic and submicroscopic chromo-
somal abnormalities [23]. This will inevitably lead to
the identification of children who carry CNVs associated
with the later development of schizophrenia and other
paediatric or adult neuropsychiatric phenotypes, which
raises ethical and practical issues.
In terms of diagnostics, the observation that CNVs are
not disorder-specific but cross diagnostic boundaries
presents difficulties, as these pleiotropic effects challenge
current psychiatric diagnosis and current classification
systems [24]. One option is that these disorders be
considered separate syndromes (for example, ‘2p16.3
deletion syndrome’ or ‘NRXN1 deletion syndrome’).
However, patients with schizophrenia who have patho-
genic CNVs are not obviously unusual in their pheno-
type [17] and to classify them as having separate
syndromes, given that the penetrance of CNV mutations
is incomplete and that other factors may be involved in
the disease, may not make sense. Only when there is a
fuller understanding of the role of both CNVs and
common and rare sequence variants (for example, SNPs)
in susceptibility, together with an understanding of the
genetic and environmental factors which modify pene-
trance and phenotype, may it be possible to diagnose
phenotype on the basis of genetics.
In terms of genetic counselling and risk assessment,
genetic and environmental factor research is likely to
lead to validated clinical tests to assess psychosis risk in
the long term, which will gradually replace the current
family history-based assessment of risk [25,26]. Genetic
counselling is likely to have an important role in
bridging research and clinical practice in psychiatry.
While there are controversies relating to predictive testing
in mental illness that cannot be dismissed [27,28], there
may be considerable benefits; these include addressing
misconceptions about the illness, reducing guilt and
stigma, and introducing adaptive strategies and non-
directive support for decision making, resulting in
improvements in quality of life, compliance with
medication, and reduction in risky behaviours [29]. In
a recent study of schizophrenia [30], no affected
individuals and only 1 in 20 relatives had received
genetic counselling. However, over 40% indicated that
their family planning decisions were influenced by
having schizophrenia in their family, and over 70%
thought genetic counselling would be useful.
However, there are considerable ethical issues to be
considered, especially as schizophrenia commonly
occurs during adolescence or early adulthood. In some
cases, schizophrenia may be preceded by idiopathic
developmental delay in childhood [31] and therefore the
implications of genetic testing of children must be
considered. Since, unlike in Mendelian disorders, no
definite genetic factors that predict the development of
schizophrenia have been established so far and since
there are considerable ethical and societal issues relating
to mental illness and prenatal diagnosis, prenatal testing
is not appropriate in this context.
Questions of ethics most commonly centre on whether
there is a clear clinical benefit to be gained from learning
the genetic status of the patient, before symptoms of
schizophrenia or another disorder develop. Genetic
testing is most likely to occur in high-risk groups, such
as children with idiopathic ‘non-chromosomal’ intellec-
tual and motor developmental delay [31,32] who might
present to clinical genetic services, those at high genetic
risk because of family history of the disease (about 10%
risk) [33], or people who have prodromal symptoms
(30% risk of conversion to full-blown psychosis) [34].
Delays and/or abnormalities in motor and language
development, intellectual and cognitive impairment,
disturbances in emotional and behavioural functioning
as well as social and interpersonal maladjustment are all
childhood antecedents of schizophrenia [32] which
might trigger genetic screening and the identification of
pathogenic CNVs; perhaps 5% of children referred to
clinical genetic testing for these reasons will later develop
schizophrenia.
Genetic testing may be beneficial in a clinical genetic
context for families with a history of schizophrenia. In
these families, the identification of a case who has an
isolated de novo CNV not present in the parents would
indicate a reduction in risk for other family members,
as the de novo mutation is a rare event and unlikely to
re-occur. On the other hand, if a parent carried the
CNV, risk would be higher as it could be passed on to
offspring. Family history of psychosis may also have a
significant impact on penetrance of CNVs, as is seen in
haemochromatosis gene (HFE)-related haemochro-
matosis. In a scenario in which an unaffected parent is
found to carry the mutation, the risk of disease to future
offspring is modulated by family history; there is an
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offspring who is homozygous for C282Y mutation and
has no family history compared with 10% if there is
a closely related affected relative, with the same
HFE haplotype in both cases. This mediation of the
penetrance appears to result from concomitant muta-
tions in other iron master genes [35]. Thus, in a family
with a history of schizophrenia and a pathogenic CNV,
the risk to offspring of a carrier of a pathogenic CNV may
be substantially higher than indicated by the population
prevalence.
Predictive testing might be conceived as useful if it were
able to stratify risk and act as an ‘early warning’ system
for intervention; this could be used in a preventative
sense in order, for example, to reduce harmful behaviour
in those at high risk or to attempt to reduce the duration
of untreated psychosis (DUP), which averages 1-2 years
for people who develop schizophrenia [36]. A reduction
of DUP may confer clinical benefits [37]. In addition,
better predictive tools in certain high-risk groups, such as
prodromal patients in whom antipsychotic medication is
being trialled to prevent onset of psychosis or improve
course [38], have the potential to better target medi-
cations and reduce their unnecessary use. However, the
benefits of drug treatment in prodromal psychosis are
as yet unclear, and in any case, the implications of
a pathogenic de novo CNV for progression to full-blown
psychosis are at present unknown, and this will need
careful assessment given their low penetrance. Thus,
while these are potential areas of clinical use, there is
little good evidence that, at present, clear clinical benefit
would be gained from learning the genetic status of the
patient. Despite this, commercial genetic testing compa-
nies are marketing tests directly to consumers based on
discoveries from genome-wide association studies. This
may carry some benefits (for example, in relation to lung
cancer or obesity risk, in which lifestyle changes such as
smoking cessation or exercise are very effective). How-
ever, in the absence of evidence of clinical validity or
utility this may be premature, especially for diseases
such as schizophrenia that are severe or carry stigma, and
has led to calls for greater discussion of the policy
implications [39,40].
The complex ethical issues, coupled with the potential
for adverse psychological effects that might accompany
genetic testing and the risk of stigmatisation of indivi-
duals at ‘high risk’, need to be weighted against the
potential benefits (genetic counselling and psychoedu-
cation of patients and relatives, early detection of illness
and implementation of treatment, and minimisation of
risk behaviours) [26,27,29,30]. Knowledge of these
dilemmas is a first step to resolving them, something
that the medical profession will need to attend to in the
near term [41].
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